Advent Capital Management Has Decreased Its Clovis Oncology (CLVS) Stake; Profile of 6 Analysts Covering Curtiss-Wright (CW)

February 17, 2018 - By Migdalia James

Advent Capital Management decreased Clovis Oncology Inc (CLVS) stake by 73.33% reported in 2017Q3 SEC filing. Advent Capital Management sold 13,750 shares as Clovis Oncology Inc (CLVS)’s stock declined 20.61%. The Advent Capital Management holds 5,000 shares with $412,000 value, down from 18,750 last quarter. Clovis Oncology Inc now has $2.65B valuation. The stock decreased 0.79% or $0.43 during the last trading session, reaching $54.15. About 675,404 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 17, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Among 8 analysts covering Curtiss-Wright (NYSE:CW), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Curtiss-Wright had 23 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating by Stifel Nicolaus given on Friday, October 27. The firm has “Buy” rating by SunTrust given on Monday, June 5. The firm earned “Buy” rating on Monday, January 8 by SunTrust. As per Friday, November 11, the company rating was downgraded by Bank of America. As per Tuesday, January 16, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating given on Friday, October 16 by CL King. As per Thursday, January 19, the company rating was initiated by Suntrust Robinson. The firm has “Neutral” rating by CL King given on Friday, November 11. On Monday, September 18 the stock rating was initiated by Stifel Nicolaus with “Hold”. Wells Fargo maintained it with “Market Perform” rating and $120 target in Friday, October 27 report. See Curtiss-Wright Corporation (NYSE:CW) latest ratings:

16/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $139.0 Maintain
16/01/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Outperform Old Target: $120 Upgrade
08/01/2018 Broker: SunTrust Rating: Buy New Target: $137.0 Maintain
10/12/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $126.0 Maintain
05/12/2017 Broker: Robert W. Baird Rating: Outperform New Target: $149 Initiates Coverage On
30/10/2017 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade
26/10/2017 Broker: SunTrust Rating: Buy New Target: $132.0 Maintain
27/10/2017 Broker: Wells Fargo Rating: Market Perform Old Target: $100 New Target: $120 Maintain
27/10/2017 Broker: Stifel Nicolaus Rating: Hold Old Target: $117 New Target: $124 Maintain
18/10/2017 Broker: SunTrust Rating: Buy New Target: $128.0 Maintain

Since September 28, 2017, it had 5 buys, and 10 insider sales for $2.93 million activity. The insider Jakubowitz Harry sold $211,788. Ferdenzi Paul J sold $733,385 worth of stock. Nathman John B also sold $152,462 worth of Curtiss-Wright Corporation (NYSE:CW) shares. On Monday, January 8 the insider Heise Rita J. bought $22,698. $10,542 worth of stock was bought by Farkas K Christopher on Tuesday, January 9. The insider Quinly Tom P bought $21,189. $169,862 worth of Curtiss-Wright Corporation (NYSE:CW) was sold by FULLER S MARCE.

Investors sentiment increased to 1.24 in Q3 2017. Its up 0.36, from 0.88 in 2017Q2. It is positive, as 21 investors sold Curtiss-Wright Corporation shares while 65 reduced holdings. 33 funds opened positions while 74 raised stakes. 32.85 million shares or 0.93% less from 33.16 million shares in 2017Q2 were reported. Wellington Management Group Incorporated Llp owns 227,387 shares or 0.01% of their US portfolio. New York-based State Common Retirement Fund has invested 0.01% in Curtiss-Wright Corporation (NYSE:CW). Boston Partners stated it has 0.18% in Curtiss-Wright Corporation (NYSE:CW). First Tru L P invested in 6,725 shares or 0% of the stock. Ontario – Canada-based Manufacturers Life Insurance The has invested 0.01% in Curtiss-Wright Corporation (NYSE:CW). 21,500 are owned by Bb&T. Envestnet Asset Management invested in 2,661 shares. State Treasurer State Of Michigan stated it has 0.01% of its portfolio in Curtiss-Wright Corporation (NYSE:CW). Ameriprise Fincl Inc invested in 0.02% or 342,766 shares. Smith Asset Mngmt Group Inc Limited Partnership accumulated 11,780 shares. Tower Cap Ltd (Trc) stated it has 0.05% of its portfolio in Curtiss-Wright Corporation (NYSE:CW). 119,948 were reported by American Int Gru. Credit Agricole S A has invested 0% of its portfolio in Curtiss-Wright Corporation (NYSE:CW). Endurance Wealth Mngmt holds 0.08% or 4,676 shares in its portfolio. Welch And Forbes Ltd Liability holds 3,000 shares or 0.01% of its portfolio.

The stock increased 1.40% or $1.76 during the last trading session, reaching $127.25. About 195,589 shares traded. Curtiss-Wright Corporation (NYSE:CW) has risen 4.96% since February 17, 2017 and is uptrending. It has underperformed by 11.74% the S&P500.

Curtiss-Wright Corporation, together with its subsidiaries, designs, makes, and overhauls precision components, and engineered services and products primarily to the aerospace, defense, power generation, and general industrial markets worldwide. The company has market cap of $5.62 billion. The firm operates through three divisions: Commercial/Industrial, Defense, and Power. It has a 26.41 P/E ratio. The Commercial/Industrial segment offers industrial vehicle products, such as electronic throttle control devices and transmission shifters; sensors, controls and electro-mechanical actuation components, and utility systems used in commercial aircrafts; valves primarily to the industrial and naval defense markets; and surface technology services, including shot peening, laser peening, coatings, and advanced testing.

Since August 15, 2017, it had 0 buys, and 5 insider sales for $1.12 million activity. The insider IVERS-READ GILLIAN C sold $208,500. On Monday, January 8 the insider SPICKSCHEN THORLEF sold $292,365.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 56 analyst reports since September 10, 2015 according to SRatingsIntel. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Buy” rating by Suntrust Robinson on Friday, August 5. The stock has “Hold” rating by WallachBeth Capital on Monday, May 9. The stock has “Buy” rating by Stifel Nicolaus on Monday, January 23. The rating was maintained by Piper Jaffray on Monday, November 16 with “Neutral”. J.P. Morgan maintained the stock with “Buy” rating in Thursday, June 1 report. On Friday, January 13 the stock rating was initiated by Morgan Stanley with “Overweight”. The firm has “Hold” rating by Oppenheimer given on Monday, July 31. The firm has “Buy” rating by Leerink Swann given on Monday, September 18. On Thursday, September 10 the stock rating was maintained by WallachBeth Capital with “Buy”. Chardan Capital Markets initiated Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Tuesday, October 25. Chardan Capital Markets has “Sell” rating and $15 target.

Advent Capital Management increased Integrated Device Tech (Prn) stake by 6.98M shares to 65.23M valued at $69.80 million in 2017Q3. It also upped Bank Of America Corp stake by 7,254 shares and now owns 57,633 shares. Calamp Corp (Prn) was raised too.

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.37, from 1.81 in 2017Q2. It dropped, as 48 investors sold CLVS shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. 40,000 were reported by Argentiere Cap Ag. Raymond James Fincl Svcs Advisors holds 12,465 shares. First Mercantile reported 0.1% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Css Il reported 100 shares or 0% of all its holdings. Fmr Lc has invested 0.02% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Cornerstone Cap Ltd reported 0.01% stake. Columbia Wanger Asset Limited Liability Corp holds 581,660 shares or 0.71% of its portfolio. Deutsche Bancorp Ag invested in 223,638 shares. Rock Springs LP has 231,500 shares. Wolverine Asset Management Ltd Limited Liability Company reported 7,735 shares stake. Amer Century accumulated 70,432 shares or 0.01% of the stock. D E Shaw Com Incorporated accumulated 202,412 shares. Us Bankshares De has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). 26,780 were reported by Kennedy Cap Inc. Partner Fund Mgmt Limited Partnership has invested 0.36% in Clovis Oncology, Inc. (NASDAQ:CLVS).

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on February, 28. They expect $-1.27 earnings per share, up 30.60% or $0.56 from last year’s $-1.83 per share. After $-1.24 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 2.42% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: